NCT01949090View on ClinicalTrials.gov

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

PHASE2CompletedINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

September 25, 2013

Primary Completion Date

December 4, 2013

Study Completion Date

October 23, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Investigational H7N1 vaccine GSK2789869A

Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.

BIOLOGICAL

Placebo

Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.

Trial Locations (8)

33024

GSK Investigational Site, Hollywood

40509

GSK Investigational Site, Lexington

66219

GSK Investigational Site, Lenexa

67207

GSK Investigational Site, Wichita

83642

GSK Investigational Site, Meridian

B2N 1L2

GSK Investigational Site, Truro

P3E 1H5

GSK Investigational Site, Greater Sudbury

M9W 4L6

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01949090 - Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older | Biotech Hunter | Biotech Hunter